Referred TestsMaximizing Clinical Utility in Oncology Through Disease-Specific NGS Panels
Share this:
With input from Mayo Clinic oncologists, our laboratories developed a menu of next-generation sequencing (NGS) oncology panels. These panels aid in the diagnosis and management of patients with cancer and are optimized for clinically relevant genes and actionable targets consistent with current oncology guidelines.
Solid Tumors
GIST-Targeted Gene Panel by Next-Generation Sequencing, Tumor
(Mayo ID: GISTP)
Tests for the presence of a mutation in the KIT and PDGFRA genes.
Additional Resources
Gastrointestinal Stromal Tumor Panel—Rondell P. Graham, M.B.B.S.
Lung Cancer-Targeted Gene Panel with Rearrangement, Tumor
(Mayo ID: LNGPR)
Tests for the presence of a mutation in the EGFR, BRAF, KRAS, HRAS, NRAS, ALK, ERBB2, and MET genes. Tests for the presence of translocations in the ALK, ROS1, RET, and NTRK1 genes.
Additional Resources
Lung Cancer Testing Brochure
Melanoma-Targeted Gene Panel by Next-Generation Sequencing, Tumor
(Mayo ID: MELP)
Tests for the presence of a mutation in the BRAF, GNA11, GNAQ, KIT, and NRAS genes.
Neuro-Oncology Expanded Panel with Rearrangement, Tumor
(Mayo ID: NONCP)
This test interrogates targeted regions across 219 genes associated with a variety of adult and pediatric CNS tumors to assess for the presence of somatic mutations and rearrangements, including mutations in IDH1/2, TERT, ATRX, TP53, H3F3A, HIST1H3B/C, BRAF, SMARCB1, and SMARCA4, and rearrangements involving RELA, BRAF, and EGFR (eg, EGFR vIII).
See Targeted Gene Regions below for details regarding the targeted gene regions identified by this test.
Additional Resources
Neuro-Oncology Testing Brochure
Informative Cases from Mayo Clinic
Test in Focus—Robert Jenkins, M.D.
RAS/RAF-Targeted Gene Panel by Next-Generation Sequencing, Tumor
(Mayo ID: RASFP)
Tests for the presence of a mutation in the following genes: BRAF, HRAS, NRAS, and KRAS.
Sarcoma Targeted Gene Fusion/Rearrangement Panels, Next-Generation Sequencing, Tumor
(Mayo ID: SARCP)
This test uses RNA-based next-generation sequencing to evaluate sarcomas for gene fusions that involve at least 1 of 138 genes. It can aid in diagnosing specific soft tissue and bone tumors (sarcoma) based on the observed gene fusions (eg, PAX3/FOXO1 gene fusion observed in alveolar rhabdomyosarcoma, EWSR1-FLI1 gene fusion for Ewing�s sarcoma, SS18-SSX1/2 genefusion for synovial sarcoma).
Solid Tumor-Targeted Cancer Gene Panel by Next-Generation Sequencing
(Mayo ID: CAPN)
Tests for the presence of a mutation in the following 50 genes: ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, and VHL.
Hematologic Malignancies
OncoHeme Next-Generation Sequencing for Myeloid Neoplasms
(Mayo ID: NGSHM)
This test includes next-generation sequencing to evaluate for the following 42 genes and intronic regions: ANKRD26, ASXL1, BCOR, CALR, CBL, CEBPA, CSF3R, DDX41, DNMT3A,ELANE, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, KDM6A, KIT, KRAS, MPL, NPM1, NRAS, PHF6, PTPN11, RAD21, RUNX1, SETBP1, SH2B3, SF3B1, SRP72, SMC3, SRSF2, STAG2,TERT, TET2, TP53, U2AF1, WT1, and ZRSR2.
Next-Generation Sequencing (NGS), Acute Myeloid Leukemia, 11-Gene Panel
(Mayo ID: NGAML)
This test includes next-generation sequencing to evaluate for the following 11 genes: CEBPA, DNMT3A, FLT3, IDH1, IDH2, KIT, KRAS, NPM1, NRAS, RUNX1, and TP53.
Next-Generation Sequencing Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel
(Mayo ID: NGAMT)
This test includes next-generation sequencing to evaluate for the following 4 genes: FLT3, IDH1, IDH2, and TP53.
Additional Resources
NGS Testing for Hematologic Malignancies Brochure
Next-Generation Sequencing for Myeloid Malignancies—David Viswanatha, M.D.
NGSMM Next-Generation Sequencing (NGS), Multiple Myeloma
(Mayo ID: NGSMM)
This test includes next-generation sequencing to evaluate for the following 61 genes and intronic regions: AKT1, AKT2, AKT3, AKT3-G, ATM, B2M, BIRC2, BIRC3, BRAF, CCND1, CD38, CDK4, CDK7, CDKN1B, CDKN2A, CDKN2A-G, CRBN, CUL4A, CUL4B, CXCR4, DIS3, DIS3-G, EGFR, FAM46C, FGFR3, FGFR3-G, GRB2, IDH1, IDH2, IDH3A, IFNGR2, IGF1R, IKZF1, IKZF3, IL6, IL6R, IRF4, JAK2, KDM6A, KDM6A-G, KRAS, MYC, MYD88, NFKB2, NR3C1, NRAS, NSD2, PIK3CA, PIK3CG, PIK3R1, PIK3R1-G, PIK3R2, PIM1, PIM2, PIM3, PSMA1, PSMB5, PSMB5-G, PSMD1, PSMG2, PTPN11, RB1, STAT3, TGFBR2, TLR4, TP53, TRAF3, and XBP1.
